New combo therapy for advanced cancers enters early human testing

NCT ID NCT07035249

Recruiting now Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new drug called DCSZ11 alongside standard chemotherapy or immunotherapy in 9 people with advanced or metastatic solid tumors, including head and neck cancer. The main goal is to see if the combination is safe and whether it can shrink tumors. Because it is very small and early, the results will only give a first hint of whether DCSZ11 is worth studying further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DCSZ11
What this could lead to: If it works, this could point toward a new combination treatment for advanced head and neck or other solid tumors.
What could go wrong: This is a very small, early-phase trial with only 9 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dorfman-Chanarin disease head and neck squamous cell carcinoma metastatic malignant neoplasm Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DCSZ11 HNSCC SOLID TUMORS

Contacts and locations

Locations

Sichuan University West China Hospital, Chengdu, Sichuan
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.